Product imageResearch use only

CAT. NO. DC60215Featured

Moderna Lipid 29

Research highlights

Selected lead from squaramide amino-lipid SARN:P 3.4 in modified ethanol-drop nanoprecipitation>20-fold luciferase AUEC versus lipid 1 in miceTwofold higher Emax and >6-fold AUEClast versus lipid 1 in cynomolgus monkeys

Pack size & price

USD

Total$500

We match the best price and quality on market.

Ships from ShanghaiIce-pack transportPure lipid recommended

Product overview

Description & Application

Lipid 29 is an ionizable amino lipid (pKa = 6.91) from Moderna platform that has been used in combination with other lipids in the formation of lipid nanoparticles (LNPs).Administration of human erythropoietin (EPO) mRNA in lipid 29-containing LNPs increases serum EPO levels in mice.

CAS No.	2244716-55-8
Chemical Name	Moderna Lipid 29
Synonyms	Moderna Lipid-29 Lipid29，Lipid 29,-[[8-[(1-ethylnonyl)oxy]-8-oxooctyl][3-[[2-(methylamino)-3,4-dioxo-1-cyclobuten-1-yl]amino]propyl]amino]-octanoic acid, 1-octylnonyl ester
SMILES	CNC(C(C1=O)=O)=C1NCCCN(CCCCCCCC(OC(CCCCCCCC)CCCCCCCC)=O)CCCCCCCC(OC(CC)CCCCCCCC)=O
Formula	C52H97N3O6
M.Wt	860.4
Purity	>95% by ELSD-HPLC
Storage	Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping condition	Ships from Shanghai. Pure lipid is stable during ice-pack transport.
Publication	Cornebise M, et al. Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA. Advanced Functional Materials. 2022;32(8):2106727.

Literature-reported formulation composition

Component	mol%	Role
Lipid 29	Not reported	Ionizable lipid
Structural phospholipid	Not reported	structural_lipid
Phospholipid (if used)	Not reported	Helper phospholipid
PEG-lipid	Not reported	PEG lipid
Reported total	Not reported	Source values retained

Formulation calculator unavailable. The supplied article does not report the complete molar composition, so a formulation weight calculation is not available. Obtain and verify the complete composition and component molecular weights before planning component quantities.

N/P ratio3.4

Buffer & pHmRNA acetate buffer, pH 5.0 during encapsulation; buffer exchange/neutralization into PBS, pH 7.2; stored at 5 °C.

CargoModified hEPO mRNA containing miR126 and miR142 target sites; firefly luciferase mRNA in a confirmatory experiment.

Administration routeIntravenous bolus in CD-1 mice; 60-minute intravenous infusion in male cynomolgus monkeys.

Dose0.5 mg/kg hEPO mRNA in mouse expression studies; 0.1 mg/kg hEPO mRNA in cynomolgus-monkey infusion.

Animal modelCD-1 mice (n=5 for primary expression comparisons); male cynomolgus monkeys (n=6 for pharmacodynamic comparison).

Formulation processModified ethanol-drop nanoprecipitation; lipid components in ethanol were combined with mRNA in acetate buffer.

Literature-reported performance for the cited formulation

Literature-reportedMouse hEPO mRNA expressionHighest expression among tested series0.5 mg/kg IV bolus, CD-1 mice, n=5 · Lipid 1 and analog seriesArticle Fig. 1b and section 2.1

Literature-reportedMouse luciferase mRNA AUEC>20-fold versus lipid 1Whole-body bioluminescence · Lipid 1 LNPArticle Fig. S4 and section 2.1

Literature-reportedCynomolgus hEPO Emax2-fold higher0.1 mg/kg, 60-min IV infusion, n=6 · Lipid 1 LNPArticle Fig. 3

Literature-reportedCynomolgus hEPO AUEClast>6-fold higher0.1 mg/kg, 60-min IV infusion, n=6 · Lipid 1 LNPArticle Fig. 3

Reported in vivo performance

Experiment	Condition	Lipid 29 result
Mouse hEPO mRNA	0.5 mg/kg IV bolus, CD-1 mice, n=5	Highest expression among the tested tail/headgroup series; lead selected
Mouse luciferase mRNA	Whole-body bioluminescence comparison	More than 20-fold greater AUEC than lipid 1 LNPs
Cynomolgus hEPO mRNA	0.1 mg/kg, 60-min IV infusion, n=6	Approximately 2-fold higher Emax and >6-fold higher AUEClast than lipid 1
LNP structure	Cryo-EM/SAXS	Lipid 29 showed more organized multilamellar features; d-spacing 4.76 nm vs 6.56 nm for lipid 1

Additional reported findings

PEG-lipid sensitivity

Lipid 29 maintained consistent particle size and low PDI across 0-3 mol% PEG-lipid, including 0 mol%; long-term stability at very low PEG was not determined.

· Article section 2.3, Fig. 6.

Proposed lipid–mRNA interactions

Molecular-dynamics simulations indicated squaramide 29 hydrogen-bond and pi-stacking interactions with exposed RNA nucleobases/sugars; this is a mechanistic hypothesis from simulations, not a standalone efficacy guarantee.

· Article section 2.2, Fig. 4.

Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.

Cited literature for this formulation and performance datasetCornebise M, et al. Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA. Advanced Functional Materials. 2022;32(8):2106727. DOI: 10.1002/adfm.202106727
All formulation and performance values are from Cornebise et al. and apply only to the cited cargo, composition, process, dose, model and comparator.

Open-access primary article

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

N/P 3.4 is reported for the article's mRNA formulation. It is not converted into a lipid:cargo mass ratio.

Mass = concentration × volume × molecular weight

MassConcentrationVolumeMolecular weightg/mol

Enter any three values to calculate the fourth.

C₁V₁ = C₂V₂

C₁mMV₁mLC₂mMV₂mL

Enter any three values to calculate the fourth.

Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass	1 mM	5 mM	10 mM
10 mg	11.6225 mL	2.3245 mL	1.1623 mL
25 mg	29.0563 mL	5.8113 mL	2.9056 mL
50 mg	58.1125 mL	11.6225 mL	5.8113 mL
100 mg	116.2250 mL	23.2450 mL	11.6225 mL
250 mg	290.5625 mL	58.1125 mL	29.0563 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?

We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.

Pure lipid or solution — which should I choose?

Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.

How should I measure a small amount of oily or viscous lipid?

Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.

Can you support formulation optimization and scale-up?

Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.

Moderna Lipid 29

Pack size & price

Description & Application

Recommended Products

LP-01

SM-86(Lipid 5)

ALC-0315

SM-102

Acuitas A9

C12-200

C14-4

Genevant CL1 (lipid 10)

TCL053

Acuitas Lipid III-2